

Joanna Q Hudson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4477072/publications.pdf>

Version: 2024-02-01

22
papers

312
citations

840119

11
h-index

887659

17
g-index

23
all docs

23
docs citations

23
times ranked

493
citing authors

#	ARTICLE	IF	CITATIONS
1	Levetiracetam pharmacokinetics in critically ill patients undergoing renal replacement therapy. <i>Journal of Critical Care</i> , 2021, 61, 216-220.	1.0	7
2	Predictors of Hypophosphatemia and Outcomes during Continuous Renal Replacement Therapy. <i>Blood Purification</i> , 2020, 49, 700-707.	0.9	13
3	Disagreement in Estimates of Kidney Function for Drug Dosing in Obese Inpatients. <i>Journal of Pharmacy Practice</i> , 2019, 32, 41-47.	0.5	5
4	Pragmatic Use of Kidney Function Estimates for Drug Dosing: The Tide Is Turning. <i>Advances in Chronic Kidney Disease</i> , 2018, 25, 14-20.	0.6	43
5	Assessing Guideline-Directed Medication Therapy for Heart Failure in End-Stage Renal Disease. <i>American Journal of the Medical Sciences</i> , 2018, 355, 247-251.	0.4	3
6	Inadequate antibiotic dosing in patients receiving sustained low efficiency dialysis. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 1250-1256.	1.0	14
7	Simultaneous assay of multiple antibiotics in human plasma by LC-MS/MS: importance of optimizing formic acid concentration. <i>Bioanalysis</i> , 2017, 9, 469-483.	0.6	22
8	End-Stage Renal Disease Increases Rates of Adverse Glucose Events When Treating Diabetic Ketoacidosis or Hyperosmolar Hyperglycemic State. <i>Clinical Diabetes</i> , 2017, 35, 202-208.	1.2	11
9	Acute Kidney Injury in Patients Continued on Renin-Angiotensin System Blockers During Hospitalization. <i>American Journal of the Medical Sciences</i> , 2017, 353, 172-177.	0.4	5
10	Predictors of adherence to a new erythropoiesis-stimulating agent inpatient ordering policy: A cross-sectional study. <i>PLoS ONE</i> , 2017, 12, e0188390.	1.1	0
11	A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?. <i>Drugs</i> , 2017, 77, 1155-1186.	4.9	27
12	Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration. <i>Pharmacotherapy</i> , 2016, 36, 1229-1237.	1.2	23
13	Effect of α -Lipoic Acid on Oxidative Stress in End-Stage Renal Disease Patients Receiving Intravenous Iron. <i>ISRN Nephrology</i> , 2014, 2014, 1-7.	1.2	6
14	Evaluation of Warfarin Dose Requirements in Patients with Chronic Kidney Disease and End-Stage Renal Disease. <i>Pharmacotherapy</i> , 2014, 34, 695-702.	1.2	12
15	Performance of Methods to Assess Kidney Function in a Predominantly Overweight Sample of Patients with Liver Disease. <i>Renal Failure</i> , 2013, 35, 249-256.	0.8	3
16	Evaluation of antibiotic prescribing patterns in patients receiving sustained low-efficiency dialysis: opportunities for pharmacists. <i>International Journal of Pharmacy Practice</i> , 2013, 21, 55-61.	0.3	21
17	Evaluation of Vancomycin and Gentamicin Dialysis Clearance Using In Vivo and In Vitro Systems. <i>Renal Failure</i> , 2012, 34, 703-707.	0.8	11
18	Use of estimated glomerular filtration rate for drug dosing in the chronic kidney disease patient. <i>Current Opinion in Nephrology and Hypertension</i> , 2011, 20, 482-491.	1.0	32

#	ARTICLE	IF	CITATIONS
19	Estimates of Kidney Function in Obese African Americans with Chronic Kidney Disease. <i>Nephron Clinical Practice</i> , 2011, 118, c101-c108.	2.3	6
20	Assessment of Eptifibatid Clearance by Hemodialysis Using an in vitro System. <i>Blood Purification</i> , 2010, 30, 266-271.	0.9	6
21	Secondary Hyperparathyroidism in Chronic Kidney Disease: Focus on Clinical Consequences and Vitamin D Therapies. <i>Annals of Pharmacotherapy</i> , 2006, 40, 1584-1593.	0.9	15
22	Evaluation of an in vitro dialysis system to predict drug removal. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 400-405.	0.4	25